title: Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.
authors.affiliation: Centre Ophtalmologique d'Imagerie et de Laser, Paris, France.|Department of Ophthalmology, Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France.
authors.forename: S
authors.initials: S
authors.lastname: Nghiem-Buffet
authors.affiliation: Department of Ophthalmology, Pasteur II University Hospital, Nice, France.
authors.forename: S
authors.initials: S
authors.lastname: Baillif
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Regnier
authors.affiliation: Novartis Ireland Limited, Dublin, Ireland.
authors.forename: A
authors.initials: A
authors.lastname: Skelly
authors.affiliation: Real-World Evidence Solutions, IMS Health, London, UK.
authors.forename: N
authors.initials: N
authors.lastname: Yu
authors.affiliation: Department of Ophthalmology, Careggi University Hospital, Florence, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Sodi
mesh_terms: D003907:Dexamethasone; D004343:Drug Implants; D005938:Glucocorticoids; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion; D016896:Treatment Outcome
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone; D000069579:Ranibizumab